Takahashi, Masato
Ohtani, Shoichiro
Nagai, Shigenori E.
Takashima, Seiki
Yamaguchi, Miki
Tsuneizumi, Michiko
Komoike, Yoshifumi
Osako, Tomofumi
Ito, Yoshinori
Ikeda, Masahiko
Ishida, Kazushige
Nakayama, Takahiro
Takashima, Tsutomu
Asakawa, Takashi
Matsumoto, Sho
Shimizu, Daisuke
Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Funding for this research was provided by:
Chugai Pharmaceutical
Article History
Received: 8 June 2020
Accepted: 2 September 2020
First Online: 13 September 2020
Compliance with ethical standards
:
: All authors received support for third-party writing assistance for this manuscript, furnished by Katie Wilson, PhD, and Stephen Salem, BSc, both of Health Interactions. Masato Takahashi has received honoraria from AstraZeneca, Taiho, Chugai, Novartis, Pfizer, Kyowa Kirin, Eli Lilly, Daiichi Sankyo, Eisai, Allergan, Fujiyakuhin, and Nihon Medi Physics, a manuscript fee from Asahi Shimbun, grant support from Taiho, Chugai, Fujifilm Toyama Chemical, Eisai, Daiichi Sankyo, and Kyowa Kirin. Shoichiro Ohtani has received honoraria from AstraZeneca, Chugai, Pfizer, Eli Lilly, Eisai, and Daiichi Sankyo. Shigenori Nagai has received honoraria from Novartis, Pfizer, Eli Lilly, Eisai, Taiho Oncology, Nippon Kayaku, and Chugai. Seiki Takashima, Miki Yamaguchi, and Michiko Tsuneizumi have received research funding from Chugai for this study. Tomofumi Osako has received research funding from Chugai, Nippon Kayaku, and Eli Lilly, and honoraria from Chugai, Eli Lilly, and Pfizer. Yoshifumi Komoike has received honoraria from AstraZeneca, Chugai, Pfizer, Novartis, and Eli Lilly, and grant support from Daiichi Sankyo, Taiho, MSD, and Chugai. Yoshinori Ito has received grant support from Covance Japan, IQVIA Services Japan, MSD, AstraZeneca, A2 Healthcare, Novartis, Parexel, Kyowa Kirin, Chugai, Eli Lilly, Eisai, EPS, Daiichi Sankyo, and Taiho. Masahiko Ikeda has received honoraria from Chugai, Pfizer, Kyowa Kirin, Eisai, Novartis, Daiichi Sankyo, Asahi Kasei, Ono, Mundi, Taiho, Bayer, and Nippon Kayaku, and has received grant support from Hisamitsu and a consulting fee from Chugai, belongs to Japanese Breast Cancer Society as a member of Practice Guidelines Committee, and Chairman of Epidemiology and Prevention Subcommittee in Practice Guidelines Committee, Setouchi Breast Project as a director, and Chairman of Clinical Trials Committee. Kazushige Ishida had received honoraria from Chugai, Nippon Kayaku, Eisai, and Pfizer. Takahiro Nakayama has received honoraria from Chugai, Novartis, AstraZeneca, Eli Lilly, Taiho Oncology, Takeda, and Pfizer. Tsutomu Takashima has received honoraria from Chugai, Eisai, Taiho Oncology, Novartis, Pfizer, Eli Lilly, and Daiichi Sankyo. Takashi Asakawa, Sho Matsumoto, and Daisuke Shimizu are employees of and hold stocks in Chugai. Norikazu Masuda has received honoraria (e.g., lecture fees) from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, and Takeda, and has received research funding from Chugai, AstraZeneca, Kyowa Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, and Daiichi Sankyo.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.